KPV
Lys-Pro-Val
KPV is a tripeptide with cell and mouse data in experimental intestinal inflammation; FDA identified no clinical human-exposure data.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Identity not confirmed
The name may refer to different substance or product forms.
The Lys-Pro-Val sequence is defined, but KPV free base and KPV acetate are distinct substance forms. Without salt, purity, aggregation and formulation data, a product is not confirmed.
Research areas
Evidence matrix
- Molecular identity
- Partially clarified
The Lys-Pro-Val sequence is defined, but KPV free base and KPV acetate are distinct substance forms. Without salt, purity, aggregation and formulation data, a product is not confirmed.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
Findings come from cell and mouse models. FDA identified no human efficacy studies for wounds or inflammatory conditions.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationAnimal study2008
Dalmasso G et al.
Accessed:
- FDA PCAC presentation: KPV-related bulk drug substancesRegulatory source2026
U.S. Food and Drug Administration
Accessed:
Research gaps
- ·Cell and animal data establish neither clinical benefit nor other routes or blends such as KLOW.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
The primary study describes PepT1-mediated uptake and changes in NF-κB, MAP-kinase and cytokine signaling in experimental models.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationAnimal study2008
Dalmasso G et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. FDA identified no human-exposure data and no suitable nonclinical toxicology; potential immunogenicity and human risks remain unknown.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Cell and animal data establish neither clinical benefit nor other routes or blends such as KLOW.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- FDA PCAC presentation: KPV-related bulk drug substancesRegulatory source2026
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 3
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationAnimal study2008
Dalmasso G et al.
Accessed:
- FDA PCAC presentation: KPV-related bulk drug substancesRegulatory source2026
U.S. Food and Drug Administration
Accessed: